Historical Valuation
Relay Therapeutics Inc (RLAY) is now in the Fair zone, suggesting that its current forward PS ratio of 284.14 is considered Fairly compared with the five-year average of -6.01. The fair price of Relay Therapeutics Inc (RLAY) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：8.10
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Relay Therapeutics Inc (RLAY) has a current Price-to-Book (P/B) ratio of 2.32. Compared to its 3-year average P/B ratio of 1.41 , the current P/B ratio is approximately 64.98% higher. Relative to its 5-year average P/B ratio of 2.37, the current P/B ratio is about -1.86% higher. Relay Therapeutics Inc (RLAY) has a Forward Free Cash Flow (FCF) yield of approximately -17.55%. Compared to its 3-year average FCF yield of -28.99%, the current FCF yield is approximately -39.46% lower. Relative to its 5-year average FCF yield of -19.17% , the current FCF yield is about -8.41% lower.
P/B
Median3y
1.41
Median5y
2.37
FCF Yield
Median3y
-28.99
Median5y
-19.17
Competitors Valuation Multiple
AI Analysis for RLAY
The average P/S ratio for RLAY competitors is 103.59, providing a benchmark for relative valuation. Relay Therapeutics Inc Corp (RLAY.O) exhibits a P/S ratio of 284.14, which is 174.28% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RLAY
1Y
3Y
5Y
Market capitalization of RLAY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RLAY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RLAY currently overvalued or undervalued?
Relay Therapeutics Inc (RLAY) is now in the Fair zone, suggesting that its current forward PS ratio of 284.14 is considered Fairly compared with the five-year average of -6.01. The fair price of Relay Therapeutics Inc (RLAY) is between to according to relative valuation methord.
What is Relay Therapeutics Inc (RLAY) fair value?
RLAY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Relay Therapeutics Inc (RLAY) is between to according to relative valuation methord.
How does RLAY's valuation metrics compare to the industry average?
The average P/S ratio for RLAY's competitors is 103.59, providing a benchmark for relative valuation. Relay Therapeutics Inc Corp (RLAY) exhibits a P/S ratio of 284.14, which is 174.28% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Relay Therapeutics Inc (RLAY) as of Jan 10 2026?
As of Jan 10 2026, Relay Therapeutics Inc (RLAY) has a P/B ratio of 2.32. This indicates that the market values RLAY at 2.32 times its book value.
What is the current FCF Yield for Relay Therapeutics Inc (RLAY) as of Jan 10 2026?
As of Jan 10 2026, Relay Therapeutics Inc (RLAY) has a FCF Yield of -17.55%. This means that for every dollar of Relay Therapeutics Inc’s market capitalization, the company generates -17.55 cents in free cash flow.
What is the current Forward P/E ratio for Relay Therapeutics Inc (RLAY) as of Jan 10 2026?
As of Jan 10 2026, Relay Therapeutics Inc (RLAY) has a Forward P/E ratio of -4.85. This means the market is willing to pay $-4.85 for every dollar of Relay Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Relay Therapeutics Inc (RLAY) as of Jan 10 2026?
As of Jan 10 2026, Relay Therapeutics Inc (RLAY) has a Forward P/S ratio of 284.14. This means the market is valuing RLAY at $284.14 for every dollar of expected revenue over the next 12 months.